{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:49:46Z","timestamp":1747406986051},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Laryngorhinootologie"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1055\/a-1861-7315","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T23:49:30Z","timestamp":1677714570000},"page":"177-185","source":"Crossref","is-referenced-by-count":2,"title":["Endokrine Orbitopathie: Aktueller Stand der medikament\u00f6sen Therapie"],"prefix":"10.1055","volume":"102","author":[{"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universitatsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareile","family":"St\u00f6hr","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universitatsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Endokrinologie, Universitatsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Endokrinologie, Universitatsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universitatsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current Insights into the Pathogenesis of Graves\u02bc Ophthalmopathy","volume":"47","author":"RS Bahn","year":"2015","journal-title":"Horm Metab Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u02bc orbitopathy: the European Group on Graves\u02bc Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"WM Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u02bc Orbitopathy Guidelines for the Management of Graves\u02bc Orbitopathy","volume":"5","author":"L Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u02bc orbitopathy (EUGOGO) on management of GO","volume":"158","author":"L Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves\u02bc orbitopathy (EUGOGO) on management of Graves\u02bc orbitopathy","volume":"18","author":"L Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"87","author":"A Eckstein","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u02bc orbitopathy","volume":"364","author":"C Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bjophthalmol-2018-313697","article-title":"Treatment strategies for Graves\u02bc ophthalmopathy: a network meta-analysis","volume":"104","author":"X Zhou","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u02bc orbitopathy","volume":"90","author":"GJ Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u02bc orbitopathy","volume":"97","author":"L Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves\u02bc ophthalmopathy","volume":"99","author":"W Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/s-0043-116945","article-title":"Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves\u02bc Orbitopathy","volume":"49","author":"M Oeverhaus","year":"2017","journal-title":"Horm Metab Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves\u02bc orbitopathy: randomised placebo-controlled study","volume":"355","author":"MP Mourits","year":"2000","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00417-009-1214-3","article-title":"A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves\u02bc orbitopathy","volume":"248","author":"KT Johnson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves\u02bc orbitopathy: efficacy and morbidity","volume":"96","author":"S Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u02bc orbitopathy: a randomized controlled study","volume":"100","author":"M Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial","volume":"6","author":"R Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u02bc orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","author":"GJ Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u02bc orbitopathy","volume":"100","author":"MN Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u02bc ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"G Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3109\/02713683.2013.867355","article-title":"Intraocular pressure lowering effect of orbital decompression is related to increased venous outflow in Graves orbitopathy","volume":"39","author":"Z Onaran","year":"2014","journal-title":"Curr Eye Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u02bc orbitopathy","volume":"86","author":"X Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u02bc orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"GJ Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"JV Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL\u20116 Receptor Tocilizumab in Refractory Graves\u02bc Orbitopathy: National Multicenter Observational Study of 48 Patients","volume":"9","author":"L Sanchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316051","article-title":"Medical treatment in thyroid eye disease in 2020","author":"JJ Khong","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcjo.2017.07.009","article-title":"Role of methotrexate in thyroid-related orbitopathy","volume":"53","author":"A Rubinov","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/cen.13834","article-title":"Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach","volume":"89","author":"Z Sipkova","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"S 01","key":"ref29","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/IOP.0000000000001146.","article-title":"Dysthyroid Optic Neuropathy","volume":"34","author":"P Saeed","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1210\/jc.2016-1279","article-title":"Hypoxia-Dependent HIF\u20111 Activation Impacts on Tissue Remodeling in Graves\u02bc Ophthalmopathy-Implications for Smoking","volume":"101","author":"GE G\u00f6rtz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"S 01","key":"ref31","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of Thyroid Eye Disease","volume":"34","author":"JM Uddin","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of highdose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"N Curro","year":"2014","journal-title":"Thyroid"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"RS Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"TJ Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves\u02bc Hyperthyroidism: A Phase I Study","volume":"29","author":"SHS Pearce","year":"2019","journal-title":"Thyroid"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","article-title":"Surgical treatment of Graves\u02bc ophthalmopathy","volume":"26","author":"A Eckstein","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"S 01","key":"ref37","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1097\/IOP.0000000000001148","article-title":"Surgical Treatment of Diplopia in Graves Orbitopathy Patients","volume":"34","author":"A Eckstein","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1055\/s-0042-118040","article-title":"Endokrine Orbitopathie","volume":"233","author":"A Eckstein","year":"2016","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"WM Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant Graves\u02bc orbitopathy","volume":"30","author":"JV P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"}],"container-title":["Laryngo-Rhino-Otologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1861-7315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:09:04Z","timestamp":1723162144000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1861-7315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,3,1]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1861-7315","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0935-8943","1438-8685"],"issn-type":[{"type":"print","value":"0935-8943"},{"type":"electronic","value":"1438-8685"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}